A powerful medication used to treat severe schizophrenia may be changing bacteria in the gut and lungs in ways that increase the risk of dangerous health problems, according to a new study from Japan.
Researchers at Chiba University say the findings may help explain why some patients taking the antipsychotic drug clozapine develop serious constipation, intestinal blockage, pneumonia, and other potentially life-threatening complications.
The research was published in the journal Translational Psychiatry and focuses on the growing scientific interest in the connection between the gut, lungs, immune system, and brain.
Schizophrenia is a severe psychiatric disorder that affects how people think, feel, and perceive reality. Patients may experience hallucinations, false beliefs, confusion, disorganized speech, and changes in behavior. Antipsychotic medications are commonly used to help reduce symptoms and improve daily functioning.
Among these drugs, clozapine is considered one of the most effective treatments for people whose symptoms do not improve with other medications. Doctors often prescribe it as a last option for treatment-resistant schizophrenia because it can work when other therapies fail.
However, clozapine is also known for causing serious side effects. Some patients experience severe constipation so dangerous that it can lead to bowel obstruction. Others develop respiratory complications, including pneumonia. Scientists have struggled for years to understand why these problems occur together.
The researchers behind the new study suspected that the answer might involve microbes living inside the body. Trillions of bacteria naturally live in the digestive system and lungs, where they help regulate digestion, immunity, inflammation, and metabolism. Scientists increasingly believe these microbial communities may influence many diseases throughout the body.
The research team focused on what is known as the “gut-lung axis,” the idea that changes in the digestive system may affect lung health and vice versa.
To test their theory, the researchers carried out experiments using mice. Some mice received daily doses of clozapine for 14 days, while others received an inactive placebo substance.
The scientists monitored body weight, digestion, microbial populations, and chemical changes in the animals’ bodies. They also used advanced sequencing methods to examine changes in bacteria living inside the gut and lungs.
The findings showed that clozapine strongly slowed digestive movement. Mice treated with the drug produced much less feces than the placebo group, suggesting their gastrointestinal system was moving more slowly.
The treated mice also lost body weight during the experiment.
More importantly, the drug caused major changes in microbial communities throughout the body. The bacteria living in the gut and lungs became significantly altered after exposure to clozapine. Researchers found that these changes differed depending on the animal’s sex and the location being studied.
To better understand how these changes might affect health, the researchers exposed the mice to a substance called lipopolysaccharide, which triggers inflammation and mimics acute lung injury.
Mice that had received clozapine were more vulnerable to inflammatory lung damage and had lower survival rates. According to the researchers, this suggests the medication may weaken the body’s ability to respond to respiratory stress.
The study proposes that clozapine may trigger a combination of harmful effects involving disrupted microbes, slowed digestion, inflammation, and metabolic stress. Together, these changes could increase the risk of serious digestive and lung complications.
The findings are important because clozapine remains one of the few effective options for people with severe schizophrenia who do not respond to standard treatments. Many psychiatrists rely on the drug despite its risks because untreated schizophrenia can also be extremely disabling and dangerous.
The new research may eventually help doctors make clozapine treatment safer. Scientists hope future studies may lead to microbiome-based approaches such as probiotics, dietary support, or microbial monitoring to reduce side effects.
Researchers are now planning human studies to identify microbial and metabolic warning signs linked to clozapine toxicity. They also hope to study respiratory monitoring tools that could help identify patients at higher risk for complications earlier.
The work highlights a broader change happening in medicine. Scientists increasingly understand that drugs may affect entire body systems rather than only their intended targets. In this case, a psychiatric medicine may influence the gut, lungs, metabolism, immune system, and inflammatory pathways all at once.
The findings also support growing evidence that the microbiome plays an important role in overall health. Researchers now believe disruptions in gut bacteria may contribute to conditions ranging from digestive disease and obesity to depression, immune disorders, and neurological illness.
Although more studies in humans are still needed, the new research offers one possible explanation for some of clozapine’s most dangerous side effects. It may also open the door to new ways of protecting patients who rely on the medication.
For people living with severe schizophrenia, safer treatment approaches could make a major difference in long-term health and quality of life.
If you care about depression, please read studies about how dairy foods may influence depression risk, and B vitamins could help prevent depression and anxiety.
For more information about mental health, please see recent studies that ultra-processed foods may make you feel depressed, and extra-virgin olive oil could reduce depression symptoms.
Source: Chiba University.
